DDInter656 DDInter1376
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Eplerenone {u} (Compound) resembles {v} (Compound) Methyltestosterone
Eplerenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Eplerenone {u} (Compound) resembles {v} (Compound) Spironolactone
Eplerenone {u} (Compound) treats {v} (Disease) hypertension
Eplerenone {u} (Compound) binds {v} (Gene) CYP3A5
Eplerenone {u} (Compound) is included by {v} (Pharmacologic Class) Aldosterone Antagonists
Eplerenone {u} (Compound) downregulates {v} (Gene) PTPRK
Eplerenone {u} (Compound) causes {v} (Side Effect) Upper respiratory tract infection
Eplerenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Eplerenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabilone
Eplerenone (Compound) resembles Methyltestosterone (Compound)
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Eplerenone (Compound) resembles Spironolactone (Compound)
Eplerenone (Compound) treats hypertension (Disease)
Eplerenone (Compound) binds CYP3A5 (Gene)
Eplerenone (Compound) is included by Aldosterone Antagonists (Pharmacologic Class)
Eplerenone (Compound) downregulates PTPRK (Gene)
Eplerenone (Compound) causes Upper respiratory tract infection (Side Effect)
Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Nabilone